Dongwha Pharm. Ind. Co., Ltd.

Sung June Yoon

Dong Rack Choi

Yong Ho Chung

Nam Doo Kim

Jung Han Shin

Hyun S Hwang

Sang Jin Park

Jong Woo Kim

Yong Kyun Park

Sang Wook Lee

Hee Jeoung Park

Jin Soo Lee

Chi Woo Lee

Yoon Ho Jin

Wang Yong Yang

Ik Hoe Kim

Sang Hun Jung

Wan Jin Song

Eun Yi Moon

Chung Ha Choi

Geun Hyung Lee

Hae Ran Yun

Dug Keun Lee

Hee Soon Lee

Jung A Lee

Moon Sun Lee

Jae Hee Jung

Su Jin Cho

Dong Hyuk Shin

Hwan Bong Jang

Jei Man Ryu

The present invention relates to novel 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives, and more specifically, to 5-pyrimidinecarboxamide derivatives and their pharmacutically able salts, the process for preparing them, and the pharmaceutical compositions containing said compounds as active ingredients. In particular, said 5-pyrimidinecarboxamide derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as a therapeutic agent as well as a preventive agent for hepatitis B and acquired immune deficiency syndrome (AIDS).

5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives

The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing -aminomethyl- methyl- -(Z)-alkoxyiminopyrrolidine substituents causing optical activity at the -position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.

Optically active quinoline carboxylic acid derivatives with 7-pyrrolidine substituents causing optical activity and a process for the preparation thereof

The present invention relates to novel 3-nitropyridine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same as active ingredients. Methods of preparing the derivatives and pharmaceutical compositions containing the same are also disclosed. The 3-nitropyridine derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as therapeutic agents as well as preventive agents for hepatitis B and acquired immune deficiency syndrome (AIDS).

3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives

The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing 4-aminomethyl-4-methyl-3-(Z)-alkoxyirninopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.

The present invention relates to a liquid suppository composition comprising diclofenac sodium, poloxamer and at least one polymer select from the group consisting of polyethylene oxide and polyvinylpyrrolidone. The composition provides the advantages of. (1) a feel of foreign matter or discomfort does not occur when the composition is rectally administered; and (2) administration is easy and after rectal administration, the composition is neither leaked out from the anus nor shifted into the end of large intestine.

Liquid suppository composition of diclofenac sodium

The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which - -, R.sub.1, and R.sub.2 are as defined in the specification.

Arylsulfonylimidazolone derivatives as an antitumor agent

The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.

Growing community of inventors

Seoul, South Korea

Sung June Yoon